The Use of Capillary Electrophoresis in Cell and Gene Therapy and Vaccine Development
Pre-Announcement (subject to change)
Event Overview
Cell and gene therapies (CGT) and vaccines are evolving rapidly, creating increasingly demanding analytical and regulatory requirements. Methods that were acceptable just a few years ago may no longer provide the resolution, sensitivity, or characterisation needed for today’s products.
This presentation and roundtable discussion will examine the current applications of capillary electrophoresis (CE) across CGT and vaccine development, including its role in process development, product characterisation, quality control, release testing, and stability studies. CE methods can support the analysis of critical quality attributes such as nucleic acid integrity, protein purity, viral vector composition, and product-related impurities.
The presenter and panellists will also address emerging analytical challenges, evolving regulatory expectations, and potential solutions for developing robust, fit-for-purpose CE methods for next-generation CGT and vaccine products. Recent regulatory considerations increasingly emphasise comprehensive characterisation of attributes such as AAV empty/full capsid ratios, genome integrity, mRNA integrity and impurities, LNP size and encapsulation efficiency, and oligonucleotide purity.
What you need to know:
Dual-ime broadcast, with starting times as follows:
Wednesday, 4 November 2026
- Broadcast #1: 09:00 h GMT (London) / 10:00 h CET (Paris/Berlin) / 14:30 h IST (New Delhi) / 17:00 h SGT (Singapore) / 18:00 h JST (Tokyo)
- Broadcast #2: 16:00 h GMT (London) / 17:00 h CET (Paris/Berlin) / 08:00 h PST (Los Angeles) / 11:00 h EST (New York)
Duration: Approximately 60 – 90 minutes, incl. Q&A.
Who should attend?
- Professionals involved in developing, manufacturing, quality control, regulatory review, and releasing cell and gene therapies (CGT), vaccines, and advanced biotherapeutics.
- This is especially relevant to scientists, analytical development specialists, process and manufacturing teams, QA/QC professionals, regulatory experts, and researchers working with viral particles, vaccines, AAV vectors, plasmid DNA, mRNA, lipid nanoparticles, or oligonucleotides.
Related Content
Cell and gene therapy compendium: access this collection of resources to explore how you can ensure the quality, safety and efficacy of your new drug candidates using capillary electrophoresis (CE) and mass spectrometry (MS) solutions.
Discover more educational resources from SCIEX to enhance your learning.
| Presenter |
|
Prof. Dr. Cari Sänger-van de GriendScientific DirectorBioQCExpert in (bio)pharmaceutical analytical chemistry with 30 years of industrial and academic experience in method development and control strategies, including Analytical Quality by Design (AQbD), and focused on best practices and knowledge sharing.
Dr. Ewoud van TrichtScientific DirectorBioQCExpert in (bio)pharmaceutical analysis with over 18 years of industrial experience in analytical development, Quality Control, and Analytical Quality by Design (AQbD). He has contributed to diverse therapeutic modalities, including small molecules, viruses, and cells, at leading companies such as Janssen Vaccines and Sanofi Cell Therapy.
| Moderators |
|
In Collaboration with:
